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Abstract
Introduction: Closed-loop (CL) systems modulate insulin delivery according to glucose levels without nurse input.
In a prospective randomized controlled trial, we evaluated the feasibility of an automated closed-loop approach
based on subcutaneous glucose measurements in comparison with a local sliding-scale insulin-therapy protocol.
Methods: Twenty-four critically ill adults (predominantly trauma and neuroscience patients) with hyperglycemia
(glucose, ≥10 mM) or already receiving insulin therapy, were randomized to receive either fully automated closed-
loop therapy (model predictive control algorithm directing insulin and 20% dextrose infusion based on FreeStyle
Navigator continuous subcutaneous glucose values, n = 12) or a local protocol (n = 12) with intravenous sliding-
scale insulin, over a 48-hour period. The primary end point was percentage of time when arterial blood glucose
was between 6.0 and 8.0 mM.
Results: The time when glucose was in the target range was significantly increased during closed-loop therapy
(54.3% (44.1 to 72.8) versus 18.5% (0.1 to 39.9), P = 0.001; median (interquartile range)), and so was time in wider
targets, 5.6 to 10.0 mM and 4.0 to 10.0 mM (P ≤ 0.002), reflecting a reduced glucose exposure >8 and >10 mM
(P ≤ 0.002). Mean glucose was significantly lower during CL (7.8 (7.4 to 8.2) versus 9.1 (8.3 to 13.0] mM; P = 0.001)
without hypoglycemia (<4 mM) during either therapy.
Conclusions: Fully automated closed-loop control based on subcutaneous glucose measurements is feasible and
may provide efficacious and hypoglycemia-free glucose control in critically ill adults.
Trial Registration: ClinicalTrials.gov Identifier, NCT01440842.
Introduction
Abnormalities of glucose metabolism are common in criti-
cally ill patients [1,2] and are characterized by hyperglyce-
mia [3-5], hypoglycemia [6,7], and increased glucose
variability [8,9], each independently and additively
associated with higher adjusted mortality rates [10].
Mechanisms of this adversity are not fully understood but
may be related to increased susceptibility to sepsis,
endothelial dysfunction, increased oxidative stress, and
predisposition to cardiac arrhythmias [6,11].
The extent to which hyperglycemia in critical illness
should be corrected has been the focus of number of
prospective studies [12-16] with conflicting results and
remains the subject of an ongoing debate [17]. Possible
explanations are different glucose targets in the control
groups, different types of devices for blood-glucose
measurement, as well as different nutritional strategies
and varying levels of expertise with insulin therapy among
the intensive care nurses [18].
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Hypoglycemia is associated with adverse outcomes and
may have negated any beneficial effect from intensive
glucose control in those patients in whom target glucose
levels were achieved.
Existing tools for achieving desired glucose levels range
from sliding and dynamic scales, and paper-based proto-
cols to computerized protocols that advise the nursing
staff [19]. Safe implementation of insulin therapy requires
accurate and frequent glucose measurements, but even
hourly glucose measurements may fail to identify hypo-
glycemia during periods of rapid glucose change. Further,
frequent sampling may be inconvenient for the patient
and adds to the workload of the nursing staff [20].
Over the last decade, continuous subcutaneous glucose
monitoring (CGM) has emerged as a valuable tool in the
management of diabetes [21,22]. A number of studies
have investigated the accuracy of CGM devices in critical
illness and have reported acceptable CGM performance
[23-25], but the clinical efficacy and effectiveness of CGM
devices in daily-life ICU practice is not yet established.
Availability of reliable continuous subcutaneous glucose
monitoring has led to a rapid expansion of research into
closed-loop insulin delivery, documenting superior perfor-
mance compared with conventional pump therapy in type
1 diabetes [26].
The objective of the present study was to investigate the
feasibility of automated closed-loop glucose control based
on continuous subcutaneous glucose measurements in
critically ill adults.
Materials and methods
Patients and study design
The study was an investigator-initiated, prospective single-
center randomized controlled parallel-group open-label
trial performed at the 24-bed Neurosciences Critical Care
Unit (NCCU) at Addenbrooke’s Hospital, Cambridge, UK,
a tertiary trauma and neurosurgical referral center in the
East of England with approximately 900 admissions per
year (90% trauma or neurosciences patients). A separate
research nurse was responsible for all study-related
activities. Cambridge Central Research Ethics Committee
approved the study.
Study participants were recruited from May 2012 to
September 2012. All critically ill patients consecutively
admitted to NCCU were screened for eligibility. Inclusion
criteria were age 18 years and older, stay at NCCU
expected of at least 48 hours, and arterial glucose level
greater than 10.0 mM or already receiving insulin treat-
ment, including preexisting diabetes. Exclusion criteria
were diabetic ketoacidosis or hyperosmolar state, thera-
peutic hypothermia, known or suspected allergy to
insulin, fatal organ failures, significant abnormalities of
blood clotting, pregnancy, and treatment with external
cardiac pacemaker.
Written informed consent/assent was obtained before
enrolling a patient in the study, either from the patient,
or, if patients lacked capacity, from the next of kin.
Patients entered into the trial were randomized to
an automated closed-loop or local sliding-scale insulin-
therapy protocol by using the minimization method [27],
implemented in the Minim program [28] to balance
between group characteristics: Acute Physiology and
Chronic Health Evaluation II (APACHE II) score, glucose
at the time of randomization, body mass index, and
preexisting diabetes. Randomization was carried out
at the time of recruitment by the investigator by using
a dedicated study laptop.
Common study procedures
Apart from glucose control, all other aspects of patient
care, including nutritional management and treatment of
hypoglycemia and hyperglycemia, were carried out accord-
ing to local treatment protocols and were identical
between treatment arms. Actrapid insulin (Novo Nordisk,
Bagsværd, Denmark), in a concentration of 50 U in 50 ml
of 0.9% saline, was used in both treatment arms. All study-
related activities were carried out for a maximum period
of 48 hours or until the end of the NCCU stay, whichever
came first.
The study was terminated if the subject was moved out
of NCCU for more than 2 hours.
Automated closed-loop therapy
Subjects randomized to closed-loop therapy were treated
by using an automated closed-loop system comprising (a)
FreeStyle Navigator subcutaneous continuous glucose-
monitoring system (Abbott Diabetes Care, Alameda, CA,
USA), (b) a laptop computer running a model predictive
control (MPC) algorithm, and (c) two Alaris CC Plus
syringe pumps (CareFusion, Basingstoke, UK) (Figure 1).
The CGM system uses CE-marked FreeStyle Navigator
Transmitter, and a non-CE-marked investigational recei-
ver device Navigator Companion (Abbott Diabetes Care),
equivalent in its function and calibration algorithm to
CE-marked Navigator Receiver with a 1-hour warm-up
time [29]. The sensor was inserted in either the anterior
abdominal wall or the upper arm. The user interface is
shown in Figure 2.
We used a control algorithm based on the model predic-
tive control approach [30], optimized and tuned in silico
by using a computer-simulation environment validated for
glucose control in the critically ill [31]. Every 5 minutes,
the algorithm calculated insulin or, at low glucose values,
20% dextrose-infusion requirements based on minute-by-
minute real-time sensor glucose values. The insulin and
dextrose pumps were controlled automatically, and no
manual intervention was required. The calculations used
a compartment model of glucose kinetics [32], describing
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the effect of insulin on sensor glucose excursions. The
algorithm was initialized by using patient’s weight and
adapted itself to a particular patient by updating two
model parameters: a rapidly changing glucose flux cor-
recting for errors in model-based predictions, and a
slowly changing estimate of an insulin rate to maintain
euglycemia. The individualized model forecasted plasma
glucose excursions over a 1- to 1.5-hour prediction
horizon when calculating the insulin rate and a 30- to
40-minute horizon when calculating the dextrose rate.
Safety rules limited maximum insulin (50 U/h) and 20%
dextrose (200 ml/h) delivery and prevented insulin
delivery at sensor glucose below 1.2 mM of the target
glucose level. Information about enteral or parenteral
nutrition was not provided to the algorithm. The algo-
rithm requested a reference glucose measurement every
1 to 6 hours (at a sensor level below 3.5 mM every
30 minutes); frequency depended on the deviation
between sensor and reference glucose values. Reference
glucose was used to recalibrate the sensor and to direct
insulin and dextrose delivery when sensor levels were
not available, such as during the 1-hour warm-up
period. We used icuMPC algorithm version 1.0.6.
Local insulin therapy protocol
Subjects allocated to the local insulin therapy protocol fol-
lowed the usual care of a paper-based intravenous insulin-
administration protocol used in NCCU (Table 1). When
the patient’s glucose control was deemed unsatisfactory,
the bedside nurse could initiate a physician-prescribed
alteration in the paper-based scale either to increase or to
decrease the amount of insulin delivered for a given glu-
cose level, as per usual practice. Similarly, insulin or dex-
trose boluses were prescribed at the discretion of the
treating physician.
Reference glucose measurements
Arterial blood glucose measurements were made by using
an on-site blood gas analyzer (Cobas b 221; Roche Diag-
nostics, Burgess Hill, UK) at hourly intervals. As previously
described in the investigational arm, a subset of reference
glucose values was provided as the algorithm dictated, but
the remainder of the reference samples did not factor into
patient management.
In the control arm, however, the hourly reference glu-
cose values were available to the clinical team for insulin-
dose adjustments.
Figure 1 Components of the closed-loop glucose-control system.
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Assessments and data collection
Demographic and clinical characteristics, including
APACHE II scores, were collected at study initiation.
Patients were classified as having diabetes on the basis
of medical history. Treatment with corticosteroids and
inotropes was defined as treatment with these agents dur-
ing any part of the study, including those subjects already
taking these agents at study entry. From the time of rando-
mization to the time of discharge from the ICU or
48 hours after randomization, whichever came first, we
recorded all blood glucose measurements, insulin adminis-
tration, type and volume of all enteral and parenteral
nutrition and additional intravenous glucose administered,
and corticosteroid and inotrope administration.
Statistical analysis
Investigators agreed on the outcome measures and the
analysis plan in advance. The primary outcome was the
time spent in primary target-glucose range between 6.0
and 8.0 mM, as recorded by reference glucose measure-
ments. Secondary efficacy outcomes were time spent with
glucose levels between 4.0 and 10.0 mM, between 5.6 and
10.0 mM, above and below target ranges, mean and stan-
dard deviation of reference glucose, sensor accuracy
Figure 2 User interface of the closed-loop system.
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metrics, and insulin-infusion rates. Safety end points
included frequency and magnitude of significant hypogly-
cemic (<3.0 mM and <2.0 mM) and significant hyperglyce-
mic (>15 and 17 mM) episodes and other adverse events.
Utility end points included the number of the reference
glucose values requested by the algorithm and CGM
availability.
As this was a feasibility study, no formal power calcula-
tions were performed. All analyses were performed on
an intention-to-treat basis. An unpaired t test was used to
compare normally distributed variables. Nonnormally
distributed variables were compared by using a Mann-
Whitney U test. Calculations were carried out by using
SPSS Version 19 (IBM Software, Hampshire, UK). Out-
comes were calculated with GStat software, Version 1.3
(University of Cambridge, UK). Values are given as mean




In total, 37 patients were screened. The next-of-kin
refused consent in seven patients, and three patients failed
inclusion/exclusion criteria. Of the 27 randomized
subjects, two subjects left the intensive care unit within
24 hours of the study start, and one subject was initiated
on therapeutic hypothermia within 24 hours. Efficacy but
not safety data from these three subjects were excluded
from the data analysis.
Twenty-four recruited subjects were analyzed (12 closed-
loop and 12 local protocol); 21 (88%) subjects completed
the intended 48 hours, whereas the remaining three (12%)
subjects completed 24, 34, and 41 study hours because of
early discharge from the NCCU. The baseline characteris-
tics of the two groups were similar (Table 2), with compar-
able APACHE Il scores, previous diabetes status, and body
mass index. Of the 24 subjects, 11 (46%) had a history of
preexisting diabetes. The majority (83%) of participants
were already receiving insulin infusion at the time of study
enrolment. The proportion of postsurgical patients was
similar between two groups, whereas patients with major
trauma were more common in the closed-loop group.
Glucose control and insulin and dextrose administration
The time spent in the primary target glucose range (6.0 to
8.0 mM) was significantly higher during closed-loop ther-
apy (54.3% (44.1 to 72.8) versus 18.5% (0.1 to 39.9), closed-
loop versus local protocol, P = 0.001, median (interquartile
range), Table 3). These differences were more pronounced
during the first 24 hours, with a fourfold improvement of
time spent in the target glucose range (59.4% (49.0 to 71.1)
versus 14.5% (0.0 to 34.5), P = 0.001). These results
persisted when the time was spent in a wider target range
of 4.0 to 10.0 mM and 5.6 to 10.0 mM (Table 3). Time
spent at greater than 8.0 mM and 10.0 mM was signifi-
cantly lower during closed-loop therapy. The cumulative
distributions of glucose values during closed-loop therapy
and the local protocol are shown in Figure 3, documenting
comparable frequency of glucose levels <5 mM. A sample
48-hour closed-loop study is shown in Figure 4.
The mean glucose level was significantly lower during
closed-loop therapy (7.9 (7.4 to 8.2) versus 9.1 (8.3 to 13.0)
mM; P = 0.001) and more consistent among subjects in
comparison to the local protocol (Figure 5). Glucose varia-
bility assessed by the standard deviation tended to be
lower during the closed-loop therapy, without reaching
statistical significance. Reference glucose profiles shown in
Figure 6 highlight differences between the two groups.
The closed-loop system administered more insulin during
the first study hours (Figure 6, bottom panel), but overall,
no statistical difference was found in insulin infusion
between the treatments (Table 3). During closed-loop
therapy, six (50%) of 12 patients received 20% dextrose,
with a total amount less than 10 g per 24 hours, and one
patient (8%) received 28 g dextrose per 24 hours.
Nutrition and concomitant treatment
All but one patient received enteral nutrition, according to
the local NCCU protocol. One patient received both ent-
eral and parenteral nutrition. The number of calories and
carbohydrates as well as the number of feeding interrup-
tions per day was comparable between the two interven-
tions (Table 2). The proportion of patients treated with
steroids or inotropes during the 48-hour study period was
slightly higher during closed-loop therapy (Table 2).
Safety
No hypoglycaemic events (<4.0 mM) or other adverse
events occurred in either group. The numbers of patients
and the numbers of episodes with glucose >15 and 17 mM
were higher during treatment with the local protocol.
Table 1 Local intravenous insulin titration protocol
Blood glucose (mM) Insulin infusion ratesa (Units/hour)
20.0 6.0, inform physicianb
17.1-20.0 4.0, inform physicianb
14.1-17.0 3.0, inform physicianb
11.1-14.0 2.5, inform physicianb




<4.0 NIL, inform physicianb
a50 Units Insulin Actrapid in 50 ml of 0.9% saline. bTarget glucose was 7 to
10 mM, and when the glucose was outside this target, hourly infusion rates
were adjusted by the attending physician.
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Table 2 Baseline characteristics, nutritional intake, and corticosteroid and inotrope treatment of the study population
Local protocol (n = 12) Automated closed-loop (n = 12)
Age (years) 58.3 ± 12.5 62.8 ± 16.0
Male sex (n/%) 9 (75%) 9 (75%)
White ethnicity 11 (92%) 12 (100%)
Weight (kg) 83.5 (80.0-89.2) 81.4 (62.5-97.5)
BMI 27.8 (25.9-30.8) 27.1 (26.4-31.4)
APACHE II score at randomization 11.2 ± 3.4 12.9 ± 5.0
Highest APACHE II score first 24 hours of admission 13.8 ± 5.0 16.2 ± 5.4
Time between admission and study start (days) 2 (1-7) 1 (1-3)
Previous diabetes 6 (50%) 5 (42%)
Insulin infusion at study start 10 (83%) 10 (83%)
Reason for ICU admission
Medical 1 (8%) 3 (25%)
After neurosurgery 4 (33%) 4 (33%)
Trauma 7 (58%) 5 (42%)
Total energy (kcal/hour) 66.4 (17.2) 60.0 (18.4)
Total CHO (g/hour) 7.9 (1.6) 7.1 (2.2)
Feeding interruptions/day 1 (0-1.5) 2 (0-2)
Corticosteroid treatment 3 (25%) 5 (42%)
Inotrope treatment 4 (33%) 5 (42%)
Data shown are mean ± SD, median (interquartile range), or number (%). APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index.
Table 3 Results based on reference glucose and insulin-infusion data
Local protocol (n = 12) Automated closed-loop (n = 12) P
Primary end point
Time glucose in target (%) (6.0-8.0 mM) 18.5 (0.1-39.9) 54.3 (44.1-72.8) 0.001
Secondary end points
Starting glucose (mM) 10.8 (9.9-12.0) 10.0 (8.9-11.1) 0.21
Mean glucose (mM) 9.1 (8.3-13.0) 7.9 (7.4-8.2) 0.001
Standard deviation of glucose (mM) 1.9 (0.8) 1.3 (0.5) 0.089
Time spent at glucose levels (%)
4.0-10.0 mM 73.2 (21.2-89.4) 93.3 (86.5-100.0) 0.002
5.6-10.0 mM 73.2 (21.2-82.4) 92.2 (83.4-99.2) 0.001
>8.0 mM 78.4 (57.6-99.9) 39.0 (23.5-51.4) 0.001
>10.0 mM 26.8 (10.5-78.8) 6.7 (0-13.5) 0.002
<6.0 mM 0 (0-3.0) 4.6 (3.1-8.3) 0.028
<5.6 mM 0 (0-0) 0.7 (0-2.7) 0.128
<4.0 mM 0 (0-0) 0 (0-0) NA
Hypoglycemia
Episodes <4.0 mM None None
Hypoglycemia treatments None None
Hyperglycemia
Number of subjects ≥15 mM 5 (42%) 1 (8%)
Number of subjects ≥17 mM 4 (33%) 1 (8%)
Episodes ≥15 mM 11 1
Episodes ≥17 mM 13 1
Insulin-infusion data
Total units for 24 hours 40.9 (34.9-101.4) 57.4 (40.0-112.2) 0.478
Hourly infusion rate 1.7 (1.5-4.2) 2.4 (1.7-4.7) 0.478
Total dextrose infusion for 48 hours (g) 0.21 (0.0-5.2) NA NA
Data shown are mean (SD) or median (interquartile range).
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Utility assessment and sensor performance
During closed-loop therapy, the number of reference glu-
cose measurements requested by the control algorithm
was 9.5 (9.0 to 14.0) during the first 24 hours and 7.0 (4.0
to 8.0) during the second 24 hours. This translated into an
interval between sensor calibrations of 152 (105 to 160)
and 205 (180 to 360) minutes during the first and second
24 hours, respectively. Sensor performance was good, with
the median absolute deviation of 0.5 (0.3 to 1.0) mM,
median relative absolute deviation of 7.0% (3.5 to 13.0),
with 87.8% of sensor values within 20% of reference
glucose. When the sensor levels were not available, the
control algorithm directed insulin/dextrose delivery based
on hourly reference glucose measurements, which were
manually put into the algorithm. Overall, sensor unavail-
ability for the entire 48-hour study period during closed-
loop therapy was 25 (0 to 207) minutes. This translated to
5.6% of the closed-loop period, including the first hour of
Figure 3 Cumulative distribution of reference glucose values obtained during closed-loop and local treatment protocol. Dashed vertical
lines indicate the primary study target range from 6.0 to 8.0 mM. Vertical fine dashed lines indicate the wider target from 4.0 to 10.0 mM.
Figure 4 An example of the 48-hour closed-loop study. Darker red continuous line represents sensor glucose. Lighter red squares represent
reference glucose measurements used for sensor calibration. Blue line represents insulin infusion. Thin red dashed lines indicate primary target.
Dextrose infusion was not required in this study.
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the study, during which the sensor was warming up.
Excluding the mandatory first-hour sensor warm-up
period, 3.4% of the closed-loop period used reference glu-
cose values manually input. This occurred mostly during
the first 10 hours of sensor use. Two subjects required
replacement of sensor because of MRI scanning.
Discussion
We documented that automated closed-loop glucose con-
trol, based on continuous subcutaneous glucose levels, is
feasible and may significantly improve glucose levels with-
out increasing the risk of hypoglycemia in critically ill
adults. Compared with local intravenous sliding-scale ther-
apy, closed-loop therapy increased up to fourfold the time
spent in the target glucose range and reduced the time
spent at higher glucose levels. Subjects treated with closed-
loop therapy achieved consistent results, with a trend
toward reduced glucose variability without requiring nurse
interventions or decision making on insulin delivery.
Reflecting the current practice recommendations for
glucose control in the intensive care unit [33,34], we
adopted a moderate glucose target of 6.0 to 8.0 mM rather
than the tight glycemic range 4.4 to 6.1 mM of the Leuven
and NICE-SUGAR studies. The upper limit of our target
range is similar to recent consensus guidelines (<8.3 mM)
[35]. Based on our simulation work, we were confident of
achieving a target between 6.0 and 8.0 mM without
increasing the risk of hypoglycemia.
Subjects in the local-treatment protocol were treated
with an intravenous sliding-scale protocol intended to
maintain glucose in a safe target range of 7 to 10 mM
without increasing the risk of hypoglycemia. We did not
change the target range of the usual treatment for two
reasons. First, we aimed to compare current local practice
with a novel treatment; second, we could not guarantee
patient safety by changing the target range of the sliding-
scale protocol. The mean glucose level achieved during
closed-loop control was 7.8 mM and was within the range
associated with the lowest mortality in observational
studies [5,36]. Importantly, during the present study,
closed-loop therapy achieved safe glucose levels without
increasing the risk of hypoglycemia. Glucose variability, as
measured by the standard deviation, tended to be lower
during closed-loop without reaching statistical signifi-
cance. Because both hypoglycemia and glucose variability
have been associated with adverse outcomes, beneficial
effects, apart from glucose lowering, may be achieved with
closed-loop therapy.
Since the introduction of intensive insulin therapy, dif-
ferent algorithms and control systems aiming at effective
and safe glucose control have been proposed [19]. These
can range from written guidelines [12,13] and protocols
[37-40] to elementary [41,42] and advanced computerized
algorithms [43-48]. We used an advanced computer
algorithm belonging to the family of model predictive con-
trol. The control algorithm and calibration strategy was
Figure 5 Mean reference glucose per subject during closed-loop (n = 12) and local treatment protocol (n = 12). Horizontal black line
indicates the mean reference glucose in each intervention arm.
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optimized on a validated computer simulation environ-
ment for the critically ill [31] before study commencement
to ensure favorable outcomes.
Our study is the first randomized controlled trial to eval-
uate fully automated closed-loop glucose control based on
subcutaneous continuous glucose monitoring in critically
ill patients. Another closed-loop study used subcutaneous
glucose levels but was limited by a lack of a randomized
design, a system that was able to control glucose in only
one of five studied patients without manual interventions
and relatively poor sensor performance, with 64% of values
within 20% of reference glucose levels [49]. A third study,
by using a closed-loop automated system in 208 Japanese
intensive care patients, reported 88% of the time that glu-
cose was in the range of 4.0 to 10.0 mM without hypogly-
cemia [50]. However, this was a retrospective observational
study and used the STG-22 system (Nikkiso, Tokyo,
Japan), which relies on continuous intravenous glucose
measurements drawing 2 ml of blood per hour and is
expensive [51], limiting its prolonged and wider use.
We initialized the closed-loop system by using approxi-
mate body weight and a reference glucose level. The sys-
tem did not require information about nutritional intake
and was able to respond to rapid changes in caloric and
carbohydrate intake, even though a 15-minute lag exists
between blood and Navigator sensor glucose levels [52].
When sensor glucose was unavailable during warm-up or
for other technical reasons, the system used hourly arterial
blood glucose without interruptions to insulin/dextrose
delivery.
We increased accuracy of the subcutaneous continuous
glucose monitor by calibrating with arterial blood glucose
Figure 6 Glucose and insulin values during infusion. Top panel: Glucose profiles (median and interquartile range) during closed-loop and
local treatment protocol. Bottom panel: Median insulin infusion rates during closed-loop and local treatment protocol. The dashed lines
indicate the primary target range from 6 to 8 mM.
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at a frequency higher than recommended by the manufac-
turer. During the first 24 hours, calibration occurred on
average every 2.5 hours, and during the second 24 hours,
every 3.5 hours. This is comparable with the present nurse
workload. Benefits of subcutaneous glucose monitoring
compared with intravenous measurements include
reduced invasiveness, obviating the need for dedicated
venous placement and a risk of contamination from dex-
trose or other medications that may interfere with glucose
measurements. The risk of infection and thrombosis
is lower with the subcutaneous route. The subcuta-
neous sensor placement was not associated with any
complications.
The strengths of our study include the randomized con-
trolled study design, the use of hourly arterial blood glu-
cose to assess outcomes, comparability of the patient
groups, and comparable nutrition and treatment modal-
ities. Study limitations include a small sample size, a single-
center study design involving a subspecialized patient
population, and short study duration, which limits general-
izability but does not affect the main study outcomes. The
control achieved by using the sliding-scale protocol appears
suboptimal and reflects the fear of hypoglycemia in the
post-NICE-SUGAR era. Comparisons with other standard
insulin-infusion protocols would be beneficial.
In conclusion, automated closed-loop therapy, based on
subcutaneous continuous glucose measurements, is a safe
and efficacious approach for glucose control in critically ill
adults. Larger and longer-duration studies are warranted
to assess system performance. Apart from providing a tan-
gible treatment option, closed-loop systems may contri-
bute important insights into the ongoing debate about
glucose targets by providing the means to achieve uniform
and safe outcomes in comparability studies.
Key messages
• Fully automated closed-loop glucose control based on
subcutaneous sensor glucose is feasible.
• Closed-loop treatment provided safe, effective, and
consistent glucose control without increasing the risk of
hypoglycemia in a small group of patients over a 48-hour
period.
• Closed-loop treatment was superior to a local slid-
ing-scale treatment protocol.
• Nurse intervention is not required during closed-loop
treatment, apart from calibrating a subcutaneous glucose
monitor.
• Automated administration of dextrose augmented the
ability of closed-loop treatment to avoid low glucose levels.
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